Earnings call transcript: Petco Q2 2025 beats EPS expectations, stock rises

Petco Health and Wellness Company (WOOF) reported Q2 FY25 EPS of $0.05, significantly exceeding the $0.01 forecast, and revenue of $1.5 billion, leading to a 0.94% stock increase after hours. Despite a 2.3% net sales decline, the company demonstrated improved profitability with a 120 basis point gross margin expansion and raised its full-year adjusted EBITDA outlook by 16% to $385-$395 million. While InvestingPro data indicates weak overall financial health and liquidity concerns, management remains confident in its "transformation journey," focusing on operational efficiency and a return to positive comparable sales growth by 2026, despite anticipated tariff impacts in the latter half of the year.

Analysis

Petco (WOOF) reported a mixed but strategically significant second quarter, characterized by a substantial earnings beat and enhanced profitability at the expense of top-line revenue. The company delivered an earnings per share of $0.05, a 400% surprise above the $0.01 forecast, on revenue of $1.5 billion which slightly exceeded projections. This bottom-line outperformance was driven by a 120 basis point expansion in gross margin to 39.3% and a $41 million year-over-year increase in operating profit, reflecting management's successful execution on eliminating unprofitable sales and improving operational discipline. In a strong sign of confidence, Petco raised its full-year adjusted EBITDA outlook by 16% to a range of $385-$395 million. However, this progress is set against a backdrop of a 2.3% decline in net sales and a 1.4% drop in comparable sales, which the company frames as an intentional part of its transformation. An InvestingPro financial health score of 1.69 signals underlying weakness, particularly with short-term obligations exceeding liquid assets. While management is preparing for a return to growth in 2026, investors should note that the company faces significant headwinds, including a flat pet industry, tougher sales comparisons in Q3, and the escalating impact of tariffs in the second half of the year.

Key Decisions for Investors

• Investors bullish on the turnaround should view the significant EPS beat and 16% increase in full-year adjusted EBITDA guidance as strong evidence of management's successful execution on improving operational profitability, potentially presenting a value opportunity.
• Caution is warranted given the company's weak financial health score, a current ratio of 0.85 indicating potential liquidity challenges, and the expected negative impact of tariffs which will become more meaningful in Q3 and Q4.
• It is crucial to recognize this is a long-term play, as management projects a return to positive comparable sales in 2026, meaning investors should temper short-term top-line growth expectations and anticipate continued stock volatility.
• Monitor gross margin trends closely to see if they can be sustained against tariff pressures, and watch for any stabilization in customer transaction volumes as the company begins reinvesting for its 'Phase three' growth.